EA201200850A1 - Фармацевтическая композиция, содержащая олигопептиды - Google Patents

Фармацевтическая композиция, содержащая олигопептиды

Info

Publication number
EA201200850A1
EA201200850A1 EA201200850A EA201200850A EA201200850A1 EA 201200850 A1 EA201200850 A1 EA 201200850A1 EA 201200850 A EA201200850 A EA 201200850A EA 201200850 A EA201200850 A EA 201200850A EA 201200850 A1 EA201200850 A1 EA 201200850A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
oligopeptides
composition containing
containing oligopeptides
lipophilic
Prior art date
Application number
EA201200850A
Other languages
English (en)
Other versions
EA022700B1 (ru
Inventor
Маркус Эбер
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44145957&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201200850(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201200850A1 publication Critical patent/EA201200850A1/ru
Publication of EA022700B1 publication Critical patent/EA022700B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к фармацевтической композиции олигопептидов, предпочтительно циклических олигопептидов, при этом указанная композиция дополнительно содержит одно или более липофильных и/или амфифильных соединений, в присутствии или в отсутствие воды, в качестве основных ингредиентов, к применению липофильных и/или амфифильных соединений для приготовления фармацевтических композиций указанных олигопептидов и к способам приготовления указанной фармацевтической композиции.
EA201200850A 2009-12-10 2010-12-06 Фармацевтическая композиция, содержащая олигопептиды EA022700B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28531309P 2009-12-10 2009-12-10
US41662810P 2010-11-23 2010-11-23
PCT/EP2010/007396 WO2011069629A2 (en) 2009-12-10 2010-12-06 Pharmaceutical composition comprising oligopeptides

Publications (2)

Publication Number Publication Date
EA201200850A1 true EA201200850A1 (ru) 2013-01-30
EA022700B1 EA022700B1 (ru) 2016-02-29

Family

ID=44145957

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200850A EA022700B1 (ru) 2009-12-10 2010-12-06 Фармацевтическая композиция, содержащая олигопептиды

Country Status (19)

Country Link
US (1) US9433577B2 (ru)
EP (1) EP2509583B1 (ru)
JP (1) JP5946770B2 (ru)
KR (1) KR20120104316A (ru)
CN (1) CN102652015B (ru)
AU (1) AU2010330364B2 (ru)
BR (1) BR112012012862A2 (ru)
CA (1) CA2783732A1 (ru)
CL (1) CL2012001310A1 (ru)
EA (1) EA022700B1 (ru)
EC (1) ECSP12012031A (ru)
ES (1) ES2742263T3 (ru)
IL (1) IL220097A (ru)
MX (1) MX2012006450A (ru)
NZ (1) NZ601109A (ru)
PE (1) PE20121359A1 (ru)
SG (1) SG181487A1 (ru)
WO (1) WO2011069629A2 (ru)
ZA (1) ZA201205103B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010251385B2 (en) * 2009-05-20 2016-04-14 Merck Patent Gmbh Novel solid materials of {[2S, 5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them
ES2564841T3 (es) 2010-05-14 2016-03-29 The General Hospital Corporation Composiciones y métodos para identificar neoantígenos específicos de un tumor
WO2012167870A1 (en) * 2011-06-09 2012-12-13 Merck Patent Gmbh Treatment of cancers and metastases with suspensions of cilengitide in carrier
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
PE20211202A1 (es) 2017-08-24 2021-07-05 Novo Nordisk As Composiciones de glp-1 y sus usos
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580778B1 (en) * 1991-04-19 1999-08-11 LDS Technologies, Inc. Convertible microemulsion formulations
JPH06509577A (ja) * 1991-07-26 1994-10-27 スミスクライン・ビーチャム・コーポレイション Ｗ／ｏミクロエマルジョン
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
WO1998007414A1 (en) * 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
UA71608C2 (en) 1999-03-11 2004-12-15 Merck Patent Gmbh A method for producing the cyclic pentapeptide
AR036852A1 (es) * 2001-10-19 2004-10-06 Isotechnika Inc Preconcentrado de una microemulsion de analogos de ciclosporina, su metodo de preparacion y metodos para producir inmunosupresion
US6656460B2 (en) * 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
DE10228049A1 (de) 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
EP1628641A2 (en) 2003-05-19 2006-03-01 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
US7749485B2 (en) * 2004-06-03 2010-07-06 Bracco Research S.A. Liposomal assembly for therapeutic and/or diagnostic use
WO2009040049A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of acetyl- (ala10, 11)-rantes (1-14) and/or calcitonin as anti-angiogenic agents
CN101990425B (zh) * 2008-04-08 2016-01-20 默克专利股份有限公司 包含环肽的组合物和使用方法
AU2010251385B2 (en) * 2009-05-20 2016-04-14 Merck Patent Gmbh Novel solid materials of {[2S, 5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them

Also Published As

Publication number Publication date
EP2509583B1 (en) 2019-05-15
JP2013513556A (ja) 2013-04-22
WO2011069629A3 (en) 2012-03-15
PE20121359A1 (es) 2012-10-15
US9433577B2 (en) 2016-09-06
CA2783732A1 (en) 2011-06-16
KR20120104316A (ko) 2012-09-20
AU2010330364B2 (en) 2016-05-19
JP5946770B2 (ja) 2016-07-06
BR112012012862A2 (pt) 2016-08-16
ES2742263T3 (es) 2020-02-13
SG181487A1 (en) 2012-07-30
NZ601109A (en) 2014-06-27
ZA201205103B (en) 2013-03-27
US20120288539A1 (en) 2012-11-15
WO2011069629A2 (en) 2011-06-16
AU2010330364A1 (en) 2012-07-26
EA022700B1 (ru) 2016-02-29
CL2012001310A1 (es) 2012-10-12
EP2509583A2 (en) 2012-10-17
MX2012006450A (es) 2012-06-28
CN102652015B (zh) 2016-08-03
CN102652015A (zh) 2012-08-29
ECSP12012031A (es) 2012-08-31
IL220097A (en) 2017-03-30

Similar Documents

Publication Publication Date Title
EA201200850A1 (ru) Фармацевтическая композиция, содержащая олигопептиды
EA201200029A1 (ru) Фармацевтическая композиция для экстренной контрацепции
GT201400136A (es) Compuestos y métodos de benzaldehído substituído para su uso en incrementar la oxigenación de los tejidos
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
EA201200794A1 (ru) Триазолопиридины
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA201171151A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
EA200702329A1 (ru) Замещенные пирролпиридины, содержащие их композиции, способ получения и применение
EA201170772A1 (ru) Органические соединения
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
EA201370018A1 (ru) Составы рифаксимина и их применение
EA201291168A1 (ru) Фармацевтические композиции и способы их получения
EA200971140A1 (ru) Триарильные соединения и композиции, их содержащие
MX2015000813A (es) Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
EA201400537A1 (ru) 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MX348823B (es) Formulaciones estables de linaclotida.
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
EA201590887A1 (ru) Композиция
EA201300337A1 (ru) Композиция, содержащая пирипиропеновый инсектицид и основание
TR200806298A2 (tr) Farmasötik formülasyon
EA201490395A1 (ru) Способ получения фармацевтических композиций, содержащих финголимод
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ KG